Plain-English translation of NCT06807632 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing whether , a new experimental medication, works safely when combined with (an immunotherapy drug) to help people with advanced small cell lung cancer stay in remission longer. Researchers will first find the right dose of that causes few or no serious side effects, then test that dose in a larger group to see how well the treatment works.
Advanced small cell lung cancer is aggressive and often comes back quickly after initial treatment. This trial is exploring whether adding this new medication to ongoing immunotherapy could help keep the cancer under control longer and improve survival for patients.
You likely qualify if…
You likely don't qualify if…
You would take a daily pill of the medication by mouth at home, and receive the second medication as an intravenous infusion (through an IV) every four weeks at the hospital or clinic. The study has two phases: first, researchers will enroll small groups to find the safest dose, then a larger group will be enrolled to confirm safety and measure how well the treatment works. You will have regular clinic visits for blood tests, scans, and check-ins with your medical team throughout the study.
AI-generated summary from trial data · Aug 24, 2026 · Not medical advice
United States